GDC-0068: Phase Ib started

Roche disclosed in its 2Q12 earnings that it began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate GDC-0973 in combination with GDC-0068 in 108 patients with locally advanced or metas...